SLCO1B1 is an influx transporter that moves drugs into cells. Variations in SLCO1B1 may affect the blood levels of drugs that are substrates for this transporter. Statins are one of the most common classes of medications affected by this transporter. Variations that result in decreased transporter activity may result in increased statin blood levels and increase the risk of adverse effects, such as myalgia and rhabdomyolysis. SLCO1B1-based dosing guidelines are available for statins. Providers should consider genotyping patients who are initiating statin therapy or those who have experienced adverse effects to statins in the past. Genetic variants tested for SLCO1B1 are *1a, *1b,*5, *15,*17.
Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1 and Simvastatin-induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.